Articles From: Omega Announces Increase in Common Stock Dividend to Omni Bio Pharmaceutical CEO Provides Company Update


2013/4/16
Omega Healthcare Investors, Inc. (NYSE:OHI) today announced that the Company’s Board of Directors declared a common stock dividend of $0.46 per share, increasing the quarterly common dividend by $0.01 per share over the previous quarter.
Sign-up for Omega Announces Increase in Common Stock Dividend investment picks
2013/4/29
Omega Healthcare Investors, Inc. (NYSE:OHI) today announced that it is scheduled to release its earnings results for the quarter ended March 31, 2013, on Tuesday, May 7, 2013, after market close.
Sign-up for Omega Announces Release Date of First Quarter Earnings and Conference Call investment picks
2013/2/5
Omega Healthcare Investors, Inc. (NYSE:OHI) today announced that it is scheduled to release its earnings results for the quarter and year ended December 31, 2012, on Tuesday, February 12, 2013.
Sign-up for Omega Announces Release Date of Fourth Quarter Earnings and Conference Call investment picks
2013/4/25
EXTON, Pa., April 25, 2013 (GLOBE NEWSWIRE) -- Omega Flex, Inc. (Nasdaq:OFLX) today reported its results of operations for the Three Months Ended March 31, 2013: Kevin R.
Sign-up for Omega Flex Announces First Quarter Financial Results investment picks
2013/2/21
EXTON, Pa., Feb.
Sign-up for Omega Flex Announces Fourth Quarter 2012 Results investment picks
2013/3/20
EXTON, Pa., March 20, 2013 (GLOBE NEWSWIRE) -- Omega Flex, Inc. (the "Company") (Nasdaq:OFLX) announced that its English subsidiary, Omega Flex Limited ("OFL"), has reached an agreement to settle litigation related to a construction project in Milton Keynes, England that involved a number of parties and issues.
Sign-up for Omega Flex, Inc. Announces Settlement Agreement investment picks
2013/2/27
Strategic Whey Protein Acquisition Expands Capabilities to Provide Healthy Human Nutrition Products for a Healthier World HOUSTON , Feb.
Sign-up for Omega Protein Announces Acquisition of Wisconsin Specialty Protein investment picks
2013/4/24
HOUSTON , April 24, 2013 /PRNewswire/ -- Omega Protein Corporation (NYSE:OME) , a nutritional product company and a leading integrated producer of omega-3 fish oil and specialty protein products, will announce results for the first quarter ended March 31, 2013 on Tuesday, May 7, 2013 , after market close.
Sign-up for Omega Protein Announces First Quarter 2013 Earnings Conference Call investment picks
2013/5/7
HOUSTON , May 7, 2013 /PRNewswire/ -- Omega Protein Corporation (NYSE: OME) , a nutritional product company and a leading integrated producer of omega-3 fish oil and specialty protein products, today announced results for the first quarter ended March 31 , 2013.
Sign-up for Omega Protein Announces First Quarter 2013 Financial Results investment picks
2013/2/19
HOUSTON , Feb.
Sign-up for Omega Protein Announces Fourth Quarter and Full Year 2012 Earnings Conference Call investment picks
2013/3/5
HOUSTON , March 5, 2013 /PRNewswire/ -- Omega Protein Corporation (NYSE:OME) today reported financial results for the fourth quarter and full year ended December 31, 2012 .
Sign-up for Omega Protein Announces Fourth Quarter and Full Year 2012 Financial Results investment picks
2013/4/29
HOUSTON , April 29, 2013 /PRNewswire/ -- Omega Protein Corporation (NYSE: OME) , a nutritional product company and a leading integrated producer of omega-3 fish oil and specialty protein products, today announced Andrew Johannesen , Executive Vice President & Chief Financial Officer, will present at the Baird Growth Stock Conference Thursday, May 9, 2013 at 11:20 a.m. ET in Chicago, IL.
Sign-up for Omega Protein To Present At The Baird Growth Stock Conference investment picks
2013/5/9
SEATTLE , May 9, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has agreed to sell 3,903,004 shares of its common stock at a price of $4.14 per share, a two percent premium over the closing price on May 8, 2013 , for gross proceeds of $16.2 million .
Sign-up for Omeros Announces $16.2 Million Registered Direct Offering of Common Stock investment picks
2013/4/2
-- Support Advancing Initial Clinical Indication of Atypical Hemolytic Uremic Syndrome --
Sign-up for Omeros Announces Positive OMS721 Data in Model of Thrombotic Microangiopathy investment picks
2013/3/26
-- Data Predict OMS824 has Greater Brain Activity without Movement Side-Effects Seen with other PDE10 Inhibitors --
Sign-up for Omeros Announces Successful Completion of PDE10 Phase 1 Multiple Ascending Dose Trial investment picks
2013/4/10
- Adds to Earlier Data Demonstrating Potential to Restore Myelin in MS Patients - SEATTLE , April 10, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data in the most commonly used model for studying the clinical and pathological features of multiple sclerosis (MS), further advancing its development program of GPR17-targeting compounds for the treatment of MS.
Sign-up for Omeros Announces that GPR17 Antagonists Improve Function in Model of Multiple Sclerosis investment picks
2013/3/28
-- European Clinical Trial Application Submission Expected in the Second Quarter of 2013 --
Sign-up for Omeros Announces Toxicology Data that Support Advancing MASP-2 Inhibitor into Clinical Trials investment picks
2013/2/7
-- IND/CTA Submission Expected in the Second Quarter of 2013 --
Sign-up for Omeros Announces Toxicology Study Data from MASP-2 Inhibitor investment picks
2013/3/18
SEATTLE , March 18, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) , a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced financial results for the fourth quarter and year ended December 31, 2012 .
Sign-up for Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results investment picks
2013/3/19
-- Clinical Entry Planned for Second Half of 2013 --
Sign-up for Omeros Elucidates Mechanism of its PDE7 Inhibitors in Addiction investment picks
2013/4/17
-- Orphan Drug Designation Could Provide Financial Incentives and Faster Regulatory Review --
Sign-up for Omeros Files Orphan Drug Application for Treatment of Atypical Hemolytic Uremic Syndrome with OMS721 investment picks
2013/4/30
-- Centralized Procedure Used for Products that Represent Therapeutic Innovation --
Sign-up for Omeros Ophthalmology Product OMS302 Granted Eligibility for European Centralized Review investment picks
2013/4/25
-- Data Show that OMS302 Maintains Pupil Size During Lens Replacement Surgery by Not Only Promoting Mydriasis but also by Preventing Miosis --
Sign-up for Omeros Reports OMS302 Clinical Data Presented at the Annual ASCRS and ASOA Symposium and Congress investment picks
2013/5/1
-- Phase 2 Clinical Trial Slated to Begin This Year --
Sign-up for Omeros Requests Fast Track Designation for OMS824 for the Treatment of Huntington's Disease investment picks
2013/4/19
SEATTLE , April 19, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it will present additional data from recent clinical trials evaluating its ophthalmology product, OMS302, at the Annual American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Symposium and Congress taking place in San Francisco April 19-23 .
Sign-up for Omeros to Present Additional OMS302 Clinical Data at the Annual ASCRS and ASOA Symposium and Congress investment picks
2013/4/24
SEATTLE , April 24, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) , a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that it will present at the 12 th Annual Needham Healthcare Conference next week.
Sign-up for Omeros to Present at the 12th Annual Needham Healthcare Conference investment picks
2013/3/29
SEATTLE , March 29, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) , a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that it has been chosen to present at the 2013 Future Leaders in the Biotech Industry Conference.
Sign-up for Omeros to Present at the 2013 Future Leaders in the Biotech Industry Conference investment picks
2013/3/1
SEATTLE , March 1, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) , a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A.
Sign-up for Omeros to Present at the Cowen and Company 33rd Annual Health Care Conference investment picks
2013/2/6
http://media.marketwire.com/attachments/201003/577068_omnilogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=982339&ProfileId=051205&sourceType=1 DENVER, CO --
Sign-up for Omni Bio Pharmaceutical Appoints Dr. Michael Kamarck as New Director investment picks
2013/1/31
http://media.marketwire.com/attachments/201003/577068_omnilogo.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=980239&ProfileId=051205&sourceType=1 DENVER, CO --
Sign-up for Omni Bio Pharmaceutical CEO Provides Company Update investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Omega Announces Increase in Common Stock Dividend to Omni Bio Pharmaceutical CEO Provides Company Update
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity